MacroGenics faces new competition
Duality takes its Adam9-targeting conjugate into the clinic.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
Colorectal cancer is next for VEGF bispecifics
Pumitamig is the latest to be tested in first-line disease.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
A new myeloid cell engager enters the clinic
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
A mystery Moderna asset hits the clinic
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
